+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID07469072

Study Comparing Low and High Doses of Nafamostat Mesilate for Anticoagulation During Continuous Renal Replacement Therapy in ICU Patients

Led by Zhujiang Hospital · Updated on 2026-04-14

92

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the anticoagulation effects and safety of different initial doses of Nafamostat Mesilate in patients in the intensive care unit ICU undergoing Continuous Renal Replacement Therapy CRRT. This single-center, randomized, open-label, parallel-controlled clinical trial aims to determine whether a higher initial dose of Nafamostat 50 mgh compared to a lower dose 20 mgh improves filter lifespan and other related outcomes. The study includes adult ICU patients with normal coagulation function and specific body mass index criteria. Participants are randomly assigned to one of two groups receiving continuous intravenous infusion of Nafamostat Mesilate pre-filter into the CRRT circuit a low-dose group at 20 mgh and a high-dose group at 50 mgh. Dosages are adjusted based on clotting times measured after the filter to maintain target anticoagulation levels safely. The treatment continues until CRRT is stopped due to clotting, recovery, transfer, death, or bleeding complications. Standard CRRT protocols and critical care treatments are applied to all patients. During the study, participants will have regular monitoring of filter performance, blood flow rates, coagulation parameters, and safety outcomes including bleeding events and adverse drug reactions. Assessments include activated clotting time, activated partial thromboplastin time, prothrombin time, fibrinogen levels, hemoglobin, and platelet counts at multiple time points during up to 72 hours of CRRT per filter session. Researchers will evaluate filter lifespan as the primary outcome and track secondary outcomes related to filter function and patient safety throughout the treatment period.

CONDITIONS

Brief Title

Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)

Research Team

Z

Zhanguo Liu, M.D.PhD

Z

Zhanguo Liu, M.D.PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here